Compass Therapeutics (CMPX) Accumulated Expenses (2019 - 2026)
Compass Therapeutics (CMPX) posted Accumulated Expenses of $1.2 million for Q1 2026, down 89.59% sequentially from $11.4 million in Q4 2025, and down 20.58% YoY from $1.5 million in Q1 2025.
Compass Therapeutics (CMPX) Accumulated Expenses (2019 - 2026) Analysis & Trends
Compass Therapeutics has reported Accumulated Expenses for 8 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Accumulated Expenses fell 20.58% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 20.58% YoY) and the FY2025 annual result came in at $11.4 million, up 81.06% from the prior year.
- Accumulated Expenses declined to $1.2 million in Q1 2026 per CMPX's latest filing, from $11.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $11.4 million in Q4 2025 and troughed at $490000.0 in Q1 2022.
- A 5-year average of $3.6 million and a median of $2.3 million in 2024 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 618.65% in 2022, down 82.27% in 2022.
- Over 5 years, Accumulated Expenses stood at $1.6 million in 2022, then gained by 24.55% to $1.9 million in 2023, then jumped by 224.41% to $6.3 million in 2024, then soared by 81.06% to $11.4 million in 2025, then tumbled by 89.59% to $1.2 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.2 million, $11.4 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.59 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 11.38 Mn |
| Sep 30, 2025 | 2.48 Mn |
| Jun 30, 2025 | 10.99 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 6.29 Mn |
| Sep 30, 2024 | 2.69 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 5.64 Mn |
| Jun 30, 2023 | 989,000.00 |
| Mar 31, 2023 | 526,000.00 |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 5.74 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 490,000.00 |
| Dec 31, 2021 | 8.78 Mn |
| Sep 30, 2021 | 799,000.00 |